A measure of growth - but companies need to be more forthcoming with market and sales data
This article was originally published in Clinica
Executive Summary
Devices and diagnostics are growth markets; that much is sure. The top 20 companies show impressive high single-digit or mid- high-teens sales growth year-on-year...take for example at 2003 year-end Becton Dickinson +12% to $4.5bn, Fresenius +9% to $4.1bn and J&J +18.5% to $14.9bn. And after nine months GEMS +11%, Guidant +20%, Stryker +20%, Baxter +9%, Boston +21%, Zimmer +20%, etc....They measure up well in terms of sales performance quarter by quarter, and it's easy to track where the gains are being made.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.